MPM is a rare cancer with a poor prognosis2
- There are approximately 3,000 people diagnosed with MPM in the United States annually3
Until 2019, pemetrexed + cisplatin has been the only FDA-approved therapy available for patients with unresectable MPM1,2,4,5
- NovoTTF-100L delivers Tumor Treating Fields (TTFields) to selectively disrupt the rapid division of cancer cells and provide continuous action against MPM progression4
At Novocure®, we take pride having developed the first 1st-line treatment for mesothelioma in over 15 years, which may help extend patients' overall survival without increasing systemic adverse events1,2,4,5
References: 1. Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta®). The Oncologist. 2004;9(5):482-488. 2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. 3. Association of Central Cancer Registries. NAACCR Fast Stats: 2011-2015 Cancer Incidence Data for Mesothelioma. https://faststats.naaccr.org/selections.php?run=runit&output=2&statistic=1&cancer=111istry=901&year=20180003&race=1&sex=1&age=1&stage=1&series=data&data=1. Accessed August 6, 2019. 4. NovoTTF-100L Instructions For Use for Unresectable Malignant Pleural Mesothelioma. Novocure 2019. 5. FDA approves the NovoTTF-100L System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, New Jersey: Business Wire; May 23, 2019.